Treatment 6 min
Ovarian cancer: treatment after surgery and PARP inhibitors
Which chemotherapy is needed after ovarian cancer surgery, why maintenance with PARP inhibitors matters, who it suits and what to do if the cancer comes back.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
After ovarian cancer surgery, most patients are given platinum-based chemotherapy followed by maintenance treatment, most often with PARP inhibitors. Maintenance therapy has been the main change in ovarian cancer treatment in recent years. Who it suits is decided by two tests: for a BRCA mutation and for genomic instability of the tumor.
Chemotherapy after surgery
The American Cancer Society describes the standard as a platinum drug (usually carboplatin or cisplatin) combined with a taxane (paclitaxel or docetaxel), given intravenously. Usually 3 to 6 cycles are given every 3–4 weeks, depending on the stage and type of tumor.
Sometimes chemotherapy starts before surgery to shrink the tumor and make its removal more complete. Then some cycles are given before and some after. On the logic of treatment before and after surgery — see the article “Neoadjuvant and adjuvant therapy”.
For some patients with stage III disease after optimal surgery (when no lesions larger than 1 cm remain), intraperitoneal chemotherapy is considered. It can help people live longer, but it is harder to tolerate and doesn’t suit everyone.
Why surgery matters so much
In ovarian cancer, the result of treatment depends a lot on how completely the tumor is removed. When describing intraperitoneal chemotherapy, the American Cancer Society refers specifically to “optimal” surgery — when no lesions larger than 1 cm remain. That’s why ovarian cancer surgery is best done at a center with experienced gynecologic oncologists. If the extent of surgery isn’t stated in your discharge summary, ask the surgeon whether any visible lesions remained — the further plan depends on it.
Tests needed before maintenance therapy
To find out which maintenance drug will suit you, you need:
- a BRCA1 and BRCA2 mutation test — in blood or saliva (inherited) and in the tumor;
- a test for genomic instability of the tumor (HRD) — it shows whether the tumor’s DNA repair mechanism is “broken”.
More on BRCA in the article “BRCA testing: who needs it and why”. If the tests haven’t been done, it’s best to discuss them during chemotherapy so the decision is ready by the time it ends.
PARP inhibitors: how they work
PARP is an enzyme that helps the cell repair DNA damage. If the tumor already has another repair pathway disrupted (as with a BRCA mutation), blocking PARP leads to the death of tumor cells. More on targeted drugs in the article “Targeted therapy”.
The American Cancer Society describes these maintenance options after first-line platinum chemotherapy if the tumor has shrunk:
| Drug | For whom |
|---|---|
| Olaparib | with a BRCA mutation |
| Olaparib + bevacizumab | with a BRCA mutation or high genomic instability |
| Niraparib | regardless of BRCA status |
When the cancer comes back but is still platinum-sensitive, PARP inhibitors are also used as maintenance.
Side effects of PARP inhibitors
According to the American Cancer Society, the most common are:
- nausea, vomiting, loss of appetite, taste changes;
- weakness, fatigue;
- anemia — a drop in hemoglobin;
- diarrhea, pain in the abdomen, muscles and joints.
That’s why a complete blood count is checked regularly on PARP inhibitors. More on low hemoglobin in the article “Anemia in cancer”. A rare but serious complication is blood disorders (myelodysplastic syndrome, acute leukemia), so any lasting changes in blood tests should be discussed with your doctor.
CA-125: how the disease is monitored
The tumor marker CA-125 is often raised in ovarian cancer and helps track the response to treatment: a fall during chemotherapy is a good sign. But treatment decisions aren’t made on a single CA-125 value: it is assessed over time and together with imaging. Small fluctuations happen without progression too. More in the article “Tumor markers”, and you can keep a chart in the tumor marker tracker.
How chemotherapy is tolerated
Carboplatin and paclitaxel is a well-studied regimen. The most common problems are:
- low white blood cells and platelets — a blood test before every cycle;
- hair loss;
- numbness and tingling in the fingers and toes on paclitaxel — more in the article “Numbness in the hands and feet”;
- fatigue, nausea.
If numbness makes it hard to do up buttons or walk, tell your doctor straight away: the paclitaxel dose can be adjusted while the changes are still reversible.
If the cancer comes back
When the cancer recurs, timing matters. If the disease didn’t come back for at least 6–12 months after the first chemotherapy, the American Cancer Society notes that the same platinum chemotherapy can be used again. If the tumor has stopped responding to platinum, it is called platinum-resistant, and the choice of treatment is different.
One of the new options for platinum-resistant disease is mirvetuximab soravtansine, a conjugate that acts on cells with high levels of folate receptor alpha (FRα). It requires a separate tumor test.
Life on maintenance therapy
PARP inhibitors are taken as tablets at home, usually for a long time. To keep treatment going smoothly:
- take the drug at the same time each day and don’t change the dose yourself — the rules are the same as for any chemotherapy in tablets;
- have blood tests on the schedule your doctor sets — that way anemia and low platelets are caught in time;
- don’t put up with nausea — it can be treated, and sometimes simply changing the time you take the drug helps;
- report severe fatigue, breathlessness, bruising and bleeding — these are reasons for an extra blood test.
Genetics is also about your family
If you’ve been found to have an inherited BRCA1 or BRCA2 mutation, it matters for your relatives: sisters, daughters and also the men in the family. They can be tested and, if the mutation is confirmed, have monitoring and prevention. Discuss this with a genetic counselor.
Questions to ask your treating doctor
- How many cycles of chemotherapy do I need, and why?
- Have BRCA and HRD tests been done? If not, when?
- Which maintenance therapy suits me, and how long should I take it?
- How often should I have blood tests on maintenance therapy?
- What will we do if the cancer comes back?
If you’ve finished chemotherapy and want to know whether maintenance treatment is right for you, I’ll go through your records at a consultation.
Sources
- Chemotherapy for Ovarian Cancer — American Cancer Society, 2025
- Targeted Therapy for Ovarian Cancer — American Cancer Society, 2026
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
